Drugs / FSME-immune
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02511587 | Oct 2012 → Jun 2015 | — | Medical University of Vienna | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT02318069 Comparator | Jan 2015 → Feb 2016 | tick-borne encephalitis | Sormland County Council, Sweden | Completed | No outcome recorded |
| Phase 2/3 | NCT01361776 Comparator | Sep 2011 → Dec 2013 | tick-borne encephalitis | Sormland County Council, Sweden | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FSME-immune | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02318069 ↗ |
| Known as | FSME-Immun | “We investigated immunogenicity of the TBE-vaccine FSME-Immun among those aged 50+ years using the standard three-dose primary series and alternative four-dose schedules.” PMID 35101266 ↗ Jan 20221“FSME-Immun® is registered for application into the muscle.” NCT02511587 ↗ |
| Modality | Vaccine | “primary TBE vaccination with FSME-Immun” PMID 35101266 ↗ Jan 2022 |
| Route | Intramuscular | “0.5 ml im as scheduled in the 4 arms” NCT01361776 ↗ |